Peptipedia
Growth HormoneNot FDA ApprovedClinical Trials

CJC-1295 DAC

Also known as Modified GRF 1-29 DAC, Drug Affinity Complex CJC

CJC-1295 variant containing a reactive linker that binds to albumin after injection, extending half-life from minutes to 6-8 days for sustained GHRH stimulation.

Investigational - Research compound
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

1-2 mg weekly

Frequency

Weekly (some use twice weekly)

Duration

8-12 weeks typical

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 1-2 mg weekly via Subcutaneous injection, Weekly (some use twice weekly). Dose range: 1-2 mg weekly. Duration: 8-12 weeks typical.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Weekly (some use twice weekly).

Mechanism of Action

Contains a reactive linker that binds to albumin after injection. Extends half-life from minutes to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation.

Research Summary

Evidence level: clinical trials. Clinical status: Investigational - Research compound.

Side Effects & Safety

Important Warnings

  • Clinical trial discontinued
  • Prolonged effects difficult to reverse.
Injection site reactions
facial flushing
water retention
headache
prolonged effects due to 8-day half-life
potential histamine release

References

No references available.

Related Peptides

Browse all →
IpamorelinGrowth Hormone

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

View profile
CJC-1295Growth Hormone

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

View profile
TesamorelinGrowth Hormone

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

View profile